Adverse Oral Reactions Associated with Low Doses of Methotrexate
N. V. Izmozherova,
A. A. Popov,
E. F. Gaysina,
M. N. Dobrinskaya,
V. M. Bakhtin,
M. K. Shatunova,
A. M. Zakhvatoshina https://doi.org/10.30895/2312-7821-2020-8-4-205-210
Abstract
Doctors of various medical specialties often encounter adverse drug reactions in their clinical practice. Methotrexate (MTX) can cause adverse reactions in the oral cavity, primarily erosions and ulcerations. The aim of the study was to analyse scientific literature on the prevalence, pathophysiological mechanisms, risk factors for oral lesions associated with low doses of MTX, their prevention and treatment. It was demonstrated that the most frequent oral adverse reactions associated with low doses of MTX are hard-to-heal painful necrotic and often irregularly shaped lesions of the oral mucosa (including aphthae and ulcers). The spectrum of histopathological changes ranges from nonspecific ulcerations to lichenoid reactions. Treatment of oral lesions induced by low doses of MTX consists in drug withdrawal or dose tapering. Folic acid and local symptomatic therapy can also be used, if necessary. Practitioners should be aware of the potential development of MTX-induced oral lesions, and specific aspects of the drug pharmacokinetics and pharmacodynamics in order to be able to ensure timely detection of adverse reactions and their effective treatment.
About the Authors
N. V. Izmozherova
Ural State Medical University
Russian Federation
Russian Federation
Nadezhda V. Izmozherova, Dr. Sci. (Med.), Associate Professor.
3 Repina St., Ekaterinburg 620028
A. A. Popov
Ural State Medical University
Russian Federation
Russian Federation
Artem A. Popov, Dr. Sci. (Med.), Associate Professor.
3 Repina St., Ekaterinburg 620028
E. F. Gaysina
Ural State Medical University
Russian Federation
Russian Federation
Elena F. Gaysina, Cand. Sci. (Med.), Associate Professor.
3 Repina St., Ekaterinburg 620028
M. N. Dobrinskaya
Ural State Medical University
Russian Federation
Russian Federation
Maria N. Dobrinskaya, Cand. Sci. (Med.), Associate Professor.
3 Repina St., Ekaterinburg 620028
V. M. Bakhtin
Ural State Medical University
Russian Federation
Russian Federation
Viktor M. Bakhtin.
3 Repina St., Ekaterinburg 620028
M. K. Shatunova
Ural State Medical University
Russian Federation
Russian Federation
Maria K. Shatunova.
3 Repina St., Ekaterinburg 620028
A. M. Zakhvatoshina
Ural State Medical University
Russian Federation
Russian Federation
Anna M. Zakhvatoshina.
3 Repina St., Ekaterinburg 620028
References
1. Gaies E, Jebabli N, Trabelsi S, Salouage I, Charfi R, Lakhal M, Klouz A. Methotrexate side effects: review article. J Drug Metab Toxicol. 2012;3(4):1–5. https://doi.org/10.4172/2157-7609.1000125
2. Yildiz H, Tayci I, Yildiz Ö, Demir MV. Pancytopenia and stomatitis induced by low-dose methotrexate use. CHRISMED J Health Res. 2017;4(1):52–4. https://doi.org/10.4103/2348-3334.196068
3. Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur J Med Chem. 2018;158:502–16. https://doi.org/10.1016/j.ejmech.2018.09.027
4. de Rotte MC, den Boer E, de Jong PH, Pluijm SM, Ćalasan MB, Weel AE, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(2):408–14. https://doi.org/10.1136/annrheumdis-2013-203725
5. Alexeeva EI, Dvoryakovskaya TM, Nikishina IP, Denisova RV, Podchernyaeva NS, Sukhorukikh OA, et al. Systemic lupus erythematosus: clinical recommendations. Part 2. Voprosy sovremennoj pediatrii = Current Pediatrics. 2018;17(2):110–25 (In Russ.) https://doi.org/10.15690/vsp.v17i2.1877
6. Galushko EA, Nasonov EL. Prevalence of rheumatic diseases in Russia. Alʹmanah klinicheskoj mediciny = Almanac of Clinical Medicine. 2018;46(1):32–9 (In Russ.) https://doi.org/10.18786/2072-0505-2018-46-1-32-39
7. Caprin AD, Starinskiy VV, Petrova GV, eds. The state of cancer care for the population of Russia in 2018. Moscow; 2019 (In Russ)
8. Souza CFD, Suarez OMZ, Silva TFM, Gorenstein ACLA, Quintella LP, Avelleira JCR. Ulcerations due to methotrexate toxicity in a psoriasis patient. An Bras Dermatol. 2016;91(3):375–7. https://doi.org/10.1590/abd1806-4841.20163960
9. Horie N, Kawano R, Kaneko T, Shimoyama T. Methotrexate-related lymphoproliferative disorder arising in the gingiva of a patient with rheumatoid arthritis. Aust Dent J. 2015;60(3):408–11. https://doi.org/10.1111/adj.12235
10. Chamorro-Petronacci C, García-García A, Lorenzo-Pouso AI, Gómez-García FJ, Padín-Iruegas ME, Gándara-Vila P, et al. Management options for low-dose methotrexate-induced oral ulcers: a systematic review. Med Oral Patol Oral Cir Bucal. 2019;24(2):e181–e189. https://doi.org/10.4317/medoral.22851
11. Kalantzis A, Marshman Z, Falconer DT, Morgan PR, Odell EW. Oral effects of low-dose methotrexate treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(1):52–62. https://doi.org/10.1016/j.tripleo.2004.08.020
12. Annussek T, Szuwart T, Kleinheinz J, Koiky C, Wermker K. In vitro inhibition of HUVECs by low dose methotrexate — insights into oral adverse events. Head Face Med. 2014;10:19. https://doi.org/10.1186/1746-160X-10-19
13. Lalani R, Lyu H, Vanni K, Solomon DH. Low-dose methotrexate and mucocutaneous adverse events: results of a systematic literature review and meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken). 2020;72(8):1140–6. https://doi.org/10.1002/acr.23999
14. Nakarmi S, Pudasaini K, Adhikari B, Vaidya B. Adverse events profile of low-dose methotrexate in nepalese patients with rheumatoid arthritis: an observational study. J Nepal Health Res Counc. 2020;18(3):360–5. https://doi.org/10.33314/jnhrc.v18i3.2743
15. West J, Ogston S, Foerster J. Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials. PLoS One. 2016;11(5):e0153740. https://doi.org/10.1371/journal.pone.0153740
16. Pedrazas CH, Azevedo MN, Torres SR. Oral events related to low-dose methotrexate in rheumatoid arthritis patients. Braz Oral Res. 2010;24(3):368–73. https://doi.org/10.1590/s1806-83242010000300018
17. Liu L, Liu S, Wang C, Guan W, Zhang Y, Hu W, et al. Folate supplementation for methotrexate therapy in patients with rheumatoid arthritis: a systematic review. J Clin Rheumatol. 2019;25(5):197–202. https://doi.org/10.1097/RHU.0000000000000810
18. Ferguson NN, Asarch A, VanBeek M, Swick BL. Acute mucocutaneous methotrexate toxicity associated with interface dermatitis and numerous eosinophils. Am J Dermatopathol. 2013;35(4):e63–6. https://doi.org/10.1097/DAD.0b013e31827b7674
19. Souza CF, Suarez OM, Silva TF, Gorenstein AC, Quintella LP, Avelleira JC. Ulcerations due to methotrexate toxicity in a psoriasis patient. An Bras Dermatol. 2016;91(3):375–7. https://doi.org/10.1590/abd1806-4841.20163960
20. Furukawa S, Oobu K, Moriyama M, Kawano S, Sako S, Hayashida JN, et al. Oral methotrexate-related lymphoproliferative disease presenting with severe osteonecrosis of the jaw: a case report and literature review. Intern Med. 2018;57(4):575–81. https://doi.org/10.2169/internalmedicine.8946-17
21. Ishida M, Hodohara K, Yoshii M, Okuno H, Horinouchi A, Nakanishi R, et al. Methotrexate-related Epstein-Barr virus-associated lymphoproliferative disorder occurring in the gingiva of a patient with rheumatoid arthritis. Int J Clin Exp Pathol. 2013;6(10):2237–41.
22. Horie N, Kawano R, Kaneko T, Shimoyama T. Methotrexate-related lymphoproliferative disorder arising in the gingiva of a patient with rheumatoid arthritis. Aust Dent J. 2015;60(3):408–11. https://doi.org/10.1111/adj.12235.
23. Dervisoglou T, Matiakis A. Oral ulceration due to methotrexate treatment: A report of 3 cases and literature review. Balkan Journal of Dental Medicine. 2015;19(2):116–20. https://doi.org/10.1515/bjdm-2015-0045
24. Akagi T, Mukai T, Fujita S, Yamamoto T, Fukuda M, Morita Y. Severe oral stomatitis due to reactivation of herpes simplex virus type 1 in a methotrexate-treated patient with dermatomyositis. Immunol Med. 2020:1–5. https://doi.org/10.1080/25785826.2020.1787585
25. Shea B, Swinden MV, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;2013(5):CD000951. https://doi.org/10.1002/14651858.CD000951.pub2
26. Sugita J, Matsushita T, Kashiwazaki H, Kosugi M, Takahashi S, Wakasa K, et al. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD. Bone Marrow Transplant. 2012;47(2):258–64. https://doi.org/10.1038/bmt.2011.53
27. Troeltzsch M, von Blohn G, Kriegelstein S, Woodlock T, Gassling V, Berndt R, Troeltzsch M. Oral mucositis in patients receiving low-dose methotrexate therapy for rheumatoid arthritis: report of 2 cases and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115(5):e28–33. https://doi.org/10.1016/j.oooo.2012.12.008
28.
Supplementary files
Review
For citations:
Izmozherova N.V., Popov A.A., Gaysina E.F., Dobrinskaya M.N., Bakhtin V.M., Shatunova M.K., Zakhvatoshina A.M. Adverse Oral Reactions Associated with Low Doses of Methotrexate. Safety and Risk of Pharmacotherapy. 2020;8(4):205-210. (In Russ.) https://doi.org/10.30895/2312-7821-2020-8-4-205-210
Views:
5042
Email this article 